Literature DB >> 10815658

X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression.

E R Melhem1, D J Loes, C S Georgiades, G V Raymond, H W Moser.   

Abstract

BACKGROUND AND
PURPOSE: Early assignment of disease progression among patients with X-linked adrenoleukodystrophy (ALD) is critical for the appropriate selection of effective therapy. We evaluated the association between contrast enhancement on T1-weighted spin-echo MR images and disease progression.
METHODS: Clinical charts of patients with X-linked ALD were reviewed for age, availability of MR images of the brain, severity of neurologic impairment, and duration and number of follow-up evaluations. Forty-three male patients with X-linked ALD had undergone multiple MR imaging examinations of the brain that consisted of at least sagittal and axial T1-weighted spin-echo, axial double-echo spin-echo, and contrast-enhanced axial T1-weighted spin-echo imaging. The MR images were reviewed for the presence of contrast enhancement. In addition, global disease burden, as shown by the double-echo spin-echo images, was assessed using a visual scoring method (Loes score).
RESULTS: Enhancement was seen on the initial T1-weighted spin-echo MR images of 21 (49%) patients; 18 (86%) of the 21 patients had disease progression revealed by the follow-up evaluations based on MR imaging (Loes) and neurologic scores. No enhancement was seen on the initial T1-weighted spin-echo MR images of 22 (51%) patients; for 18 (82%) of the 22 patients, no evidence of disease progression was revealed by the follow-up evaluations.
CONCLUSION: There is a very strong association between the presence of contrast enhancement on T1-weighted MR images and X-linked ALD progression based on clinical evaluation and MR imaging.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815658      PMCID: PMC7976769     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  18 in total

Review 1.  Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy.

Authors:  H W Moser
Journal:  Brain       Date:  1997-08       Impact factor: 13.501

2.  Adrenoleukodystrophy. A clinical and pathological study of 17 cases.

Authors:  H H Schaumburg; J M Powers; C S Raine; K Suzuki; E P Richardson
Journal:  Arch Neurol       Date:  1975-09

3.  Fatty acid abnormality in adrenoleukodystrophy.

Authors:  M Igarashi; H H Schaumburg; J Powers; Y Kishmoto; E Kolodny; K Suzuki
Journal:  J Neurochem       Date:  1976-04       Impact factor: 5.372

4.  Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging.

Authors:  E R Melhem; S N Breiter; A M Ulug; G V Raymond; H W Moser
Journal:  AJR Am J Roentgenol       Date:  1996-03       Impact factor: 3.959

Review 5.  The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome.

Authors:  W Krivit; L A Lockman; P A Watkins; J Hirsch; E G Shapiro
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 6.  X-linked adrenoleukodystrophy: biochemical diagnosis and enzyme defect.

Authors:  R J Wanders; C W van Roermund; W Lageweg; B S Jakobs; R B Schutgens; A A Nijenhuis; J M Tager
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

7.  Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.

Authors:  I Singh; A E Moser; S Goldfischer; H W Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

8.  Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells.

Authors:  B R Migeon; H W Moser; A B Moser; J Axelman; D Sillence; R A Norum
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Adrenoleukodystrophy: a scoring method for brain MR observations.

Authors:  D J Loes; S Hite; H Moser; A E Stillman; E Shapiro; L Lockman; R E Latchaw; W Krivit
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

Review 10.  The pathology of peroxisomal disorders with pathogenetic considerations.

Authors:  J M Powers
Journal:  J Neuropathol Exp Neurol       Date:  1995-09       Impact factor: 3.685

View more
  29 in total

Review 1.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

2.  Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.

Authors:  W P Miller; L F Mantovani; J Muzic; J B Rykken; R S Gawande; T C Lund; R M Shanley; G V Raymond; P J Orchard; D R Nascene
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

Review 3.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 4.  The Changing Face of Adrenoleukodystrophy.

Authors:  Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub
Journal:  Endocr Rev       Date:  2020-08-01       Impact factor: 19.871

Review 5.  Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature.

Authors:  Patricia L Musolino; Troy C Lund; Jessica Pan; Maria L Escolar; Asif M Paker; Christine N Duncan; Florian S Eichler
Journal:  Neuropediatrics       Date:  2014-01-23       Impact factor: 1.947

6.  T2 relaxation measurements in X-linked adrenoleukodystrophy performed using dual-echo fast fluid-attenuated inversion recovery MR imaging.

Authors:  E R Melhem; T F Gotwald; R Itoh; S J Zinreich; H W Moser
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 7.  Therapeutic strategies in adrenoleukodystrophy.

Authors:  Bela R Turk; Ann B Moser; Ali Fatemi
Journal:  Wien Med Wochenschr       Date:  2017-05-10

8.  Brain endothelial dysfunction in cerebral adrenoleukodystrophy.

Authors:  Patricia L Musolino; Yi Gong; Juliet M T Snyder; Sandra Jimenez; Josephine Lok; Eng H Lo; Ann B Moser; Eric F Grabowski; Matthew P Frosch; Florian S Eichler
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

9.  Adrenomyeloneuropathy, a dynamic progressive disorder: brain magnetic resonance imaging of two cases.

Authors:  Yuan-Heng Mo; Ya-Fang Chen; Hon-Man Liu
Journal:  Neuroradiology       Date:  2004-03-04       Impact factor: 2.804

10.  Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy.

Authors:  Patricia Leonor Musolino; Otto Rapalino; Paul Caruso; Verne Strudwick Caviness; Florian Sebald Eichler
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.